LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective

Mental status and physical activity in patients with homozygous familial hypercholesterolemia: A subgroup analysis of a nationwide survey (A-HIT1 registry)

(2020) Özlem Kuman Tunçel et al.   Journal of Clinical Lipidology

Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia

(2020) Claudia Stefanutti   Current Atherosclerosis Reports

Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia

(2020) Dirk J. Blom et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Therapeutic Apheresis for Management of Lp(a) Hyperlipoproteinemia

(2020) Sergei N. Pokrovsky et al.   Current Atherosclerosis Reports

Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)

(2020) James A. Underberg et al.   Journal of Clinical Lipidology

Negative impact of COVID-19 pandemic on the lifestyle and management of patients with homozygous familial hypercholesterolemia

(2020) Meral Kayikcioglu et al.   Journal of Clinical Lipidology

Bypassing the LDL Receptor in Familial Hypercholesterolemia

(2020) Sander Kersten   NEW ENGLAND JOURNAL OF MEDICINE

Evinacumab for Homozygous Familial Hypercholesterolemia

(2020) Frederick J. Raal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis in Turkey: Results of a nationwide survey (A-HIT1 registry)

(2019) Meral Kayikcioglu et al.   Journal of Clinical Lipidology

Current Role of Lipoprotein Apheresis

(2019) Gilbert Thompson et al.   Current Atherosclerosis Reports

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

(2019) Anand Padmanabhan et al.   JOURNAL OF CLINICAL APHERESIS

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

HEART UK consensus statement on Lipoprotein(a): A call to action

(2019) Jaimini Cegla et al.   ATHEROSCLEROSIS

Corrigendum to: “Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study)” [Atherosclerosis 259 (2017 Apr) 20–25]

(2018) Elisa Waldmann et al.   ATHEROSCLEROSIS

A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry)

(2018) Meral Kayikcioglu et al.   ATHEROSCLEROSIS

Toward an international consensus—Integrating lipoprotein apheresis and new lipid-lowering drugs

(2017) Claudia Stefanutti et al.   Journal of Clinical Lipidology

HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom

(2016) Michael France et al.   ATHEROSCLEROSIS

Impact of LDL apheresis on aortic root atheroma in children with homozygous familial hypercholesterolemia

(2015) Bruno Lefort et al.   ATHEROSCLEROSIS

Lipoprotein Apheresis

(2015) Patrick M. Moriarty et al.   CARDIOLOGY CLINICS

Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability and Risk of Cardiovascular Outcomes

(2015) Sripal Bangalore et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

(2015) Sotirios Tsimikas et al.   LANCET

Daily life, experience and needs of persons suffering from homozygous familial hypercholesterolaemia: Insights from a patient survey

(2014) Eric Bruckert et al.   ATHEROSCLEROSIS SUPPLEMENTS

Lipoprotein Apheresis in the Management of Familial Hypercholesterolaemia: Historical Perspective and Recent Advances

(2014) Claudia Stefanutti et al.   Current Atherosclerosis Reports

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

(2014) M. Cuchel et al.   EUROPEAN HEART JOURNAL

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

(2014) Gerald F Watts et al.   European Journal of Preventive Cardiology

Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography

(2013) Maya S. Safarova et al.   ATHEROSCLEROSIS SUPPLEMENTS

Lipoprotein apheresis: State of the art and novelties

(2013) C. Stefanutti et al.   ATHEROSCLEROSIS SUPPLEMENTS

Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

(2013) Evan A. Stein et al.   CIRCULATION

Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease

(2013) Josef Leebmann et al.   CIRCULATION

Proteomic Analysis of Proteins Eliminated by Low-Density Lipoprotein Apheresis

(2013) Yumiko Yuasa et al.   THERAPEUTIC APHERESIS AND DIALYSIS

Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment

(2012) Frederick J. Raal et al.   ATHEROSCLEROSIS

A New Model of Care for Familial Hypercholesterolaemia: What is the Role of Cardiology?

(2012) Gerald F. Watts et al.   Heart Lung and Circulation

Guidelines for the Management of Familial Hypercholesterolemia

(2012) Mariko Harada-Shiba et al.   Journal of Atherosclerosis and Thrombosis

LDL-Apheresis: Technical and Clinical Aspects

(2012) Rolf Bambauer et al.   TheScientificWorldJOURNAL

Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy

(2011) Frederick J. Raal et al.   CIRCULATION

Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia

(2011) Claudia Stefanutti et al.   CYTOKINE

Efficacy criteria and cholesterol targets for LDL apheresis

(2009) Gilbert R. Thompson et al.   ATHEROSCLEROSIS

Impact of LDL-Apheresis on inflammation and microcirculation

(2009) Michael J. Koziolek et al.   ATHEROSCLEROSIS SUPPLEMENTS

Aorta and coronary angiographic follow-up of children with severe hypercholesterolemia treated with low-density lipoprotein apheresis

(2009) Claudia Stefanutti et al.   TRANSFUSION

Low-density Lipoprotein Apheresis in Children With Familial Hypercholesterolemia: Follow-up to 21 Years

(2008) Jean-Bernard Palcoux et al.   THERAPEUTIC APHERESIS AND DIALYSIS

A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia

(2007) A. David Marais et al.   ATHEROSCLEROSIS